p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer

Cancer

Volumn 80, Issue 5, 1997, Pages 892-898

  Eltabbakh, Gamal H ^a,b   Belinson, Jerome L ^a   Kennedy, Alexander W ^a   Biscotti, Charles V ^a   Casey, Graham ^a   Tubbs, Raymond R ^a   Blumenson, Leslie E ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Multivari ate analysis; Ovarian carcinoma; P53 overexpression; Prognosis; Survival

Indexed keywords

PROTEIN P53;

ADULT; AGED; AGING; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030807593     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970901)80:5<892::AID-CNCR10>3.0.CO;2-R     Document Type: Article

References (28)

1. Kosary CL. FIGO stage, histologic grade, age, and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31-46.
2. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57: 1083-93.
3. Harris CC, Hollstein M. Clinical applications of the p53 tumor-suppressor gene. New Engl J Med 1993;329:1318-27.
4. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
5. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
6. Yamaguchi A, Kurosaka Y, Fuschida S, Kanno M, Yonemura Y, Miwa K, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2777-84.
7. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, et al. Prognostic significance of p53 mutation and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
8. Kupryjanczyk J, Thor A, Beauchamp T, Merritt V, Edegerton SM, Bell DA, et al. p53 mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90: 4961-5.
9. Hendriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-6.
10. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-3.
11. Levesque MA, Katsros D, Yu H, Zola P, Sismondi P, Giatdina G, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
12. Klemi PJ, Pylkkanen L, Kiiholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
13. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, et al. Prognostic significance of P53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12: 64-9.
14. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
15. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obster Gynecol 1993;81:643-50.
16. Allan LA, Campbell MK, Milner BJ, Eccles DM, Leonard RCF, Parkin DE, et al. The significance of p53 mutation and overexpression in ovarian cancer prognosis. Int J Gynecol Cancer 1996;6:483-90.
17. Sheridan E, Silcocks P, Smith J, Hancock BW, Goyns MH. p53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer 1994; 30A:1701-4.
18. Serov SF, Scully RE, Sobin LH. International histologic classification and staging of tumors. Histologic typing of ovarian tumors. Number 91. Geneva: World Health Organization, 1973: 37-41.
19. Cancer Committee of the International Federation of Gynecology and Obstetrics. Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 1986;25:383-5.
20. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
22. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
23. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991;6:1685-90.
24. Kim JW, Cho YH, Kwon DJ, Kim TE, Park TC, Lee JM, et al. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. Gynecol Oncol 1995;57:199-204.
25. Okamoto A, Sameshima Y, Yokoyama S, Tershima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-6.
26. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, et al p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-32.
27. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda EJ, Shaughnessy M, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
28. Sjorgen S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-82.